Shin Nishio1, Kimio Ushijima2, Tomohiko Yamaguchi3, Yuko Sasajima4, Hitoshi Tsuda4, Takahiro Kasamatsu5, Masayoshi Kage3, Mayumi Ono6, Michihiko Kuwano7, Toshiharu Kamura2. 1. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Asahi-machi 67, Kurume, Fukuoka, Japan. Electronic address: shinshin@med.kurume-u.ac.jp. 2. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Asahi-machi 67, Kurume, Fukuoka, Japan. 3. Department of Pathology, Kurume University Hospital, Asahi-machi 67, Kurume, Fukuoka 830-0011, Japan. 4. Department of Pathology and Laboratories, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. 5. Department of Gynecologic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. 6. Department of Pharmaceutical Oncology, Graduates School of Pharmaceutical Sciences, Kyushu University, Maedashi 3-5-1, Higashi-ku, Fukuoka 812-8582, Japan. 7. Laboratory of Molecular Cancer Biology, Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Maedashi 3-5-1, Higashi-ku, Fukuoka 812-8582, Japan.
Abstract
OBJECTIVE: Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many studies indicate that YB-1 is strongly expressed in tumor cells and is considered a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer. Clinical trials of EGFR family-base therapy are currently being initiated in cervical cancer. Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. However, the clinical significance of nuclear YB-1 expression in different settings, the correlation with EGFR, and the prognostic implications of YB-1 expression in cervical cancer remain elusive. PATIENTS AND METHODS: Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 patients with cervical cancer who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival, EGFR expression, and human epidermal growth factor receptor 2 (HER2) expression were investigated. RESULTS: Nuclear YB-1 expression was found in 41 (20.2%) of 204 cases of cervical cancer and correlated with disease stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with EGFR expression (P=0.0114) as well as HER2 expression (P=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor progression-free survival (P=0.0033) and overall survival (P=0.0003), respectively. CONCLUSION: Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in cervical cancer.
OBJECTIVE:Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many studies indicate that YB-1 is strongly expressed in tumor cells and is considered a marker of tumor aggressiveness and clinical prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been associated with poor outcomes in cervical cancer. Clinical trials of EGFR family-base therapy are currently being initiated in cervical cancer. Nuclear YB-1 expression correlates with EGFR expression in various types of cancer. However, the clinical significance of nuclear YB-1 expression in different settings, the correlation with EGFR, and the prognostic implications of YB-1 expression in cervical cancer remain elusive. PATIENTS AND METHODS: Nuclear YB-1 expression was immunohistochemically analyzed in tissue specimens obtained from 204 patients with cervical cancer who underwent surgery. Associations of nuclear YB-1 expression with clinicopathological factors such as survival, EGFR expression, and human epidermal growth factor receptor 2 (HER2) expression were investigated. RESULTS: Nuclear YB-1 expression was found in 41 (20.2%) of 204 cases of cervical cancer and correlated with disease stage, tumor diameter, stromal invasion, and lymph-node metastasis. Nuclear YB-1 expression also correlated with EGFR expression (P=0.0114) as well as HER2 expression (P=0.0053). Kaplan-Meier survival analysis showed that nuclear YB-1 expression was significantly associated with poor progression-free survival (P=0.0033) and overall survival (P=0.0003), respectively. CONCLUSION: Nuclear YB-1 expression is a prognostic marker and correlates with EGFR expression in cervical cancer.
Authors: Tao Guo; Shilei Zhao; Peng Wang; Xiaoyuan Xue; Yan Zhang; Mengying Yang; Nan Li; Zhuoshi Li; Lingzhi Xu; Lei Jiang; Lei Zhao; Patrick C Ma; Rafael Rosell; Jinxiu Li; Chundong Gu Journal: Oncotarget Date: 2017-07-18
Authors: Asmus Heumann; Özge Kaya; Christoph Burdelski; Claudia Hube-Magg; Martina Kluth; Dagmar S Lang; Ronald Simon; Burkhard Beyer; Imke Thederan; Guido Sauter; Jakob R Izbicki; Andreas M Luebke; Andrea Hinsch; Frank Jacobsen; Corinna Wittmer; Franziska Büscheck; Doris Höflmayer; Sarah Minner; Maria Christina Tsourlakis; Thorsten Schlomm; Waldemar Wilczak Journal: Sci Rep Date: 2017-05-17 Impact factor: 4.379